评估塔达拉菲尔在改善严重喘患者肺功能和喘严重程度方面的有效性:一项随机对照试验研究
Seyed Hamid Borsi1, Seyed Ali Asghar Fakhr Mousavi1, Mehrdad Dargahi Mal-Amir1
1Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz.
概括
作为固酶抑制剂的塔达拉菲尔在严重喘患者中没有显著改善肺功能或生活质量. 这项临床试验发现,在喘管理方面,塔达拉菲尔与安慰剂相比没有任何益处.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 固酶抑制剂增加周期性腺单酸和周期性关单酸,可能提供对喘有益的抗炎作用.
- 塔达拉菲尔是一种选择性固酶抑制剂,促使人们对其在缓解喘症状方面的有效性进行研究.
研究的目的:
- 评估塔达拉菲尔对严重喘患者肺功能和生活质量的影响.
- 为了确定塔达拉菲尔在治疗严重喘方面是否提供超越安慰剂的临床益处.
主要方法:
- 进行了一项随机的双盲临床试验,涉及44名严重喘患者.
- 参与者被分为两组:一组接受塔达拉菲尔 (每天20毫克),另一组接受安慰剂一个月.
- 测量结果包括螺旋计,喘生活质量问卷得分和6分钟步行距离.
主要成果:
- 在Tadalafil和安慰剂组之间的肺部参数中没有观察到统计学上显著的差异 (p>0.05).
- 生活质量得分和6分钟步行测试结果显示,与安慰剂相比,Tadalafil组没有显著改善 (分别为p=0.167和p=0.148).
- 一个月每天服用塔达拉菲尔 (20毫克) 对严重喘患者的临床或实验室结果没有显著改善.
结论:
- 达拉菲尔剂量为20毫克/天,持续一个月,在改善严重喘患者的肺功能或生活质量方面没有表现出有效性.
- 该研究表明,根据评估的临床和实验室结果,塔达拉菲尔不是治疗严重喘的有效治疗方法.
- 可能需要进一步的研究来探索其他固酶抑制剂或用于严重喘管理的不同治疗策略.
更多相关视频
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
302
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
302
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:24Antiasthma Drugs: Methylxanthines
231
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
231
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
158
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
158
01:26COPD: Management Using Bronchodilators and Corticosteroids
208
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
208